Foreign institutional investors (FIIs) have acquired over 4 million shares of Ranbaxy Laboratories in the January - March 2014 quarter. They held 10.79% stake in the company in December quarter.
The overseas investors have increased their stake in the company by 1.1 percentage points to 11.79% in Q4, the highest since June 2012 quarter. On the other hand, domestic institutional investors (DII) and bodies corporate have offloaded collectively nearly a two percentage point stake in the company during the quarter. Total DIIs stake in the company declined to 8.30% from 8.81% and of Bodies Corporate to 1.64% from 3.05% earlier.
Orange Mauritius Investments bought 4.55 million shares, representing 1.07% stake, in the pharmaceutical major during the March quarter, as against nil holding in December quarter.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: